Bicycle Therapeutics plc
BCYC · NASDAQ
Bulios Fair Price
$4.36
19.5% upside
Current Price
$3.65
According to Bulios Fair Price, BCYC is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Bicycle Therapeutics (BCYC) is a biotechnology company based in the United Kingdom that focuses on developing novel therapeutics based on bicycle peptide technology. This technology enables the creation of small, stable, and highly specific therapeutics with the potential to treat various diseases, including cancer and immune-related disorders. Bicycle Therapeutics is dedicated to developing drugs based on its bicycle peptide platform and building partnership agreements with pharmaceutical companies.
Sector
Healthcare
Industry
Biotechnology
CEO
Kevin Lee
Employees
288
Headquarters
Cambridge
Upcoming events
Earnings
Upcoming earnings report